Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

April 21, 2020

Primary Completion Date

December 2, 2023

Study Completion Date

March 2, 2028

Conditions
Esophageal CancerSurgeryNeoadjuvant TreatmentSurvival
Interventions
DRUG

Neoadjuvant immunochemotherapy

"Neo-adjuvant chemotherapy(cisplatin and paclitaxel):~Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles. JS001, 240mg ivgtt, d3, \>30min, 3week, 2 cycles~Surgery:~2-3weeks after Neo-adjuvant chemotherapy Surgeons: the operation shall be performed by senior thoracic surgeons. Try to achieve the consistency of operation quality.~Operation: the thoracic esophagectomy must be through right thoracic cavity. (open and minimally invasive McKeown or Ivor Lewis). Total two-field lymphadenectomy (right and left recurrent laryngeal nerve lymph nodes must be included).~After surgery/ maintain period:~JS001, 240mg ivgtt, d3, \>30min, 3week (8 cycles at most)"

Trial Locations (1)

450003

RECRUITING

Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University), Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV